Global Long-acting Insulin Glargine Market Growth 2025-2031
Description
The global Long-acting Insulin Glargine market size is predicted to grow from US$ 7802 million in 2025 to US$ 6728 million in 2031; it is expected to grow at a CAGR of -2.4% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Long-acting insulin glargine is a modified form of human insulin designed to provide a prolonged and steady release of insulin over approximately 24 hours. It helps maintain basal insulin levels in patients with diabetes mellitus, reducing the risk of blood sugar fluctuations between meals and overnight. Its unique formulation allows for once-daily dosing with minimal peak activity.
United States market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long-acting Insulin Glargine players cover Sanofi, Eli Lilly & Co, Biocon Biologics, Gan & Lee, Tonghua Dongbao, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Insulin Glargine Industry Forecast” looks at past sales and reviews total world Long-acting Insulin Glargine sales in 2024, providing a comprehensive analysis by region and market sector of projected Long-acting Insulin Glargine sales for 2025 through 2031. With Long-acting Insulin Glargine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Insulin Glargine industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Insulin Glargine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Insulin Glargine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Insulin Glargine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Insulin Glargine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Insulin Glargine.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Insulin Glargine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vial
Prefilled
Segmentation by Application:
Type 1 Diabetes
Type 2 Diabetes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Eli Lilly & Co
Biocon Biologics
Gan & Lee
Tonghua Dongbao
Biocare
United Laboratories
KALBE PHARMA
Swixx Biopharma
INFION PHARMA
Viatris
Wockhardt
Lupin Laboratories
Cipla
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Insulin Glargine market?
What factors are driving Long-acting Insulin Glargine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Insulin Glargine market opportunities vary by end market size?
How does Long-acting Insulin Glargine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Long-acting insulin glargine is a modified form of human insulin designed to provide a prolonged and steady release of insulin over approximately 24 hours. It helps maintain basal insulin levels in patients with diabetes mellitus, reducing the risk of blood sugar fluctuations between meals and overnight. Its unique formulation allows for once-daily dosing with minimal peak activity.
United States market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long-acting Insulin Glargine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long-acting Insulin Glargine players cover Sanofi, Eli Lilly & Co, Biocon Biologics, Gan & Lee, Tonghua Dongbao, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Insulin Glargine Industry Forecast” looks at past sales and reviews total world Long-acting Insulin Glargine sales in 2024, providing a comprehensive analysis by region and market sector of projected Long-acting Insulin Glargine sales for 2025 through 2031. With Long-acting Insulin Glargine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Insulin Glargine industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Insulin Glargine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Insulin Glargine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Insulin Glargine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Insulin Glargine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Insulin Glargine.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Insulin Glargine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vial
Prefilled
Segmentation by Application:
Type 1 Diabetes
Type 2 Diabetes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Eli Lilly & Co
Biocon Biologics
Gan & Lee
Tonghua Dongbao
Biocare
United Laboratories
KALBE PHARMA
Swixx Biopharma
INFION PHARMA
Viatris
Wockhardt
Lupin Laboratories
Cipla
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting Insulin Glargine market?
What factors are driving Long-acting Insulin Glargine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Insulin Glargine market opportunities vary by end market size?
How does Long-acting Insulin Glargine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
113 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Long-acting Insulin Glargine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Long-acting Insulin Glargine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
